A federal judge has approved a permanent injunction restricting a generic drug company from manufacturing and distributing certain drugs until it complies with the law, the Justice Department said Thursday.
The DOJ said the company, Ben Venue Laboratories, has been the subject of about 40 recalls since 2002, including 10 each in 2011 and 2012.
The Bedford, Ohio, company is a subsidiary of Ingelheim, German-based Boehringer Ingelheim.
The DOJ, which sought the injunction at the Food and Drug Administration's request, said Ben Venue manufactures generic sterile injectible drug products, including cancer medications. According to the agency's Jan. 22 complaint, a November-December 2011 inspection documented 10 deviations from good manufacturing practices, and the findings were similar to several previous inspections at Ben Venue's facility.